|
Sandra Calman M.D. was appointed Vice President of Clinical Development and Chief Medical Officer in February 2007. Prior to joining Isolagen Dr. Calman spent more than 15 years in various clinical roles where she successfully managed clinical research operations leading products from development through FDA approval. Dr. Calman was with Merck KgaA Dey where she served as Vice President Medical Affairs and Clinical Research and Chief Medical Officer. Previous roles include senior clinical research positions with Johnson & Johnson and Dow Pharmaceuticals where she led the clinical development program for key dermatologic and topical therapies. Dr. Calman is a Board Certified physician and received her training at the University of Utah School of Medicine where she graduated with honors. Dr. Calman is an active member of the American Academy of Family Practice and the American Academy of Dermatology.
| 